GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » XWELL Inc (NAS:XWEL) » Definitions » Capex-to-Revenue

XWELL (XWEL) Capex-to-Revenue : 0.04 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is XWELL Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

XWELL's Capital Expenditure for the three months ended in Dec. 2023 was $-0.27 Mil. Its Revenue for the three months ended in Dec. 2023 was $7.40 Mil.

Hence, XWELL's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.04.


XWELL Capex-to-Revenue Historical Data

The historical data trend for XWELL's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XWELL Capex-to-Revenue Chart

XWELL Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.52 0.10 0.12 0.08

XWELL Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.20 0.04 0.05 0.04

Competitive Comparison of XWELL's Capex-to-Revenue

For the Diagnostics & Research subindustry, XWELL's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XWELL's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where XWELL's Capex-to-Revenue falls into.



XWELL Capex-to-Revenue Calculation

XWELL's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-2.373) / 30.109
=0.08

XWELL's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.266) / 7.403
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XWELL  (NAS:XWEL) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


XWELL Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of XWELL's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


XWELL (XWEL) Business Description

Traded in Other Exchanges
N/A
Address
254 West 31st Street, 11th Floor, New York, NY, USA, 10001
XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresCheck, XpresSpa, Treat, and HyperPointe. XpresSpa is an airport retailer of wellness services and related products. Treat is a travel health and wellness brand that offers in-airport spa and wellness medical services. XpresCheck provides Covid-19 screening and diagnostic testing in partnership with the CDC. HyperPointe is a digital healthcare and data analytics relationship company.
Executives
Suzanne A. Scrabis officer: Chief Financial Officer C/O XWELL, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Scott R Milford officer: Chief Executive Officer C/O TOWN SPORTS INTERNATIONAL, LLC, 5 PENN PLAZA, NEW YORK NY 10001
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Ezra Ernst officer: See Remarks C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Omar Haynes officer: VP Treas & Fi & Interim CFO C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Doug Satzman director, officer: Chief Executive Officer 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
James A. Berry officer: Chief Financial Officer C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Michael Lebowitz director 780 THIRD AVENUE, 12TH FLOOR, C/O XPRESSPA GROUP, INC., NEW YORK NY 10017
Donald E. Stout director 780 THIRD AVENUE, 15TH FLOOR, NEW YORK NY 10017
Mistral Spa Holdings, Llc 10 percent owner C/O MISTRAL CAPITAL MANAGEMENT, LLC, 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Mistral Capital Management, Llc 10 percent owner 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Andrew R Heyer other: Former director and 10% owner 501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Calm.com, Inc. 10 percent owner 140 2ND STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Edward Jankowski officer: SVP; CEO of XpresSpa C/O FORM HOLDINGS CORP., 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017